Загрузка...
CAR T Cell Therapy for Neuroblastoma
Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with debilitating long term sequelae from treatment. Even after integration of anti-GD2 monoclonal antibody therapy into standard, upftont protocols, 5-year overall survival rates are only about 50%. The success...
Сохранить в:
| Опубликовано в: : | Front Immunol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6232778/ https://ncbi.nlm.nih.gov/pubmed/30459759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.02380 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|